



## VRL/SEC/EXCHANGE

### 13.04.2021

National Stock Exchange	of	
India Ltd.	Ť	The Stock Exchange, Mumbai
5 <sup>th</sup> Floor, Exchange Plaza	Í	25 <sup>th</sup> Floor, Phiroze Jeejeebhoy Towers
Bandra (E),	÷.	Dalal Street
Mumbai- 400 051	(Å)	Mumbai
	Ť.	

## Sub.: Press Release

Dear Sir/ Madam,

Pls find enclosed herewith press release about "Venus Remedies Enters into Partnership with West Pharmaceutical Services, Inc. to Launch Cloti-Xa™ (Enoxaparin Prefilled Syringes) in India with NovaGuard® SA Pro Safety System".

### Thanking you.

Yours faithfully, for VENUS REMEDIES LIMITED

(Company Secretary)

# **VENUS REMEDIES LIMITED**

#### Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra, Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com fwww.vmrcindia.com email : info@venusremedies.com CIN No. : L24232CH1989PLC009705 **Unit-I :** 51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India Tel. : +91-172-2933094, 2933090, 2565577, Fax : +91-172-2565566

Unit-II : Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.), Bbatoli Kalan, Baddi (H.P.) 173205, India Tel. : +91-1792-242100, 242101, Fax : +91-1795-271272

Unit-V : VENUS PHARMA GmbH AM Bahnhof 1-3, D-59368, Werne, Germany



# Venus Remedies Enters into Partnership with West Pharmaceutical Services, Inc. to Launch Cloti-Xa<sup>™</sup> (Enoxaparin Prefilled Syringes) in India with NovaGuard<sup>®</sup> SA Pro Safety System

With focus on novel solutions against unmet medical needs. Cloti-Xa<sup>™</sup> is Enoxaparin prefilled syringe with needlestick prevention mechanism offering additional protection for healthcare providers and patients against infections due to NSI.

**April 13, 2021: Panchkula, Haryana;** Venus Remedies Limited is a research and development driven global pharmaceutical company and among the leading injectable manufacturers in the world, recently announced its partnership with West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, for its new introduction in the fast-growing low molecular weight heparin market with brand Cloti-Xa<sup>™</sup>, which has adopted NovaGuard<sup>®</sup> SA Pro safety system, a single-use accessory for prefilled ISO standard 1mL long staked-needle syringes.

Cloti-Xa<sup>TM</sup> which contains enoxaparin sodium is being introduced with added advantage of NovaGuard<sup>®</sup> SA Pro safety system which is a revolutionary product that helps and protects healthcare workers and patients from accidental needlestick injuries. This innovative product has been commented to deliver a compelling total cost of ownership in that it prevents preactivation, offers a lower syringe snap-in force and a lower activation force for end-user comfort, and mitigates the practice of recapping which helps to provide tamper evidence to customers.

Mr. Saransh Chaudhary, Chief Executive Officer, Venus Medicine Research Centre said, "We are delighted to enter into a partnership with West to produce Cloti-Xa<sup>™</sup> PFS with the innovative NovaGuard<sup>®</sup> SA Pro safety system in India. Cloti-Xa<sup>™</sup> is expected to provide patients and healthcare providers with an additional advantage of safety from accidental needle stick injuries, which could lead to the spread of infections like HIV, Hepatitis B and C. So far, no other enoxaparin formulation in India seems to offer this additional benefit apart from the innovator brand. Enoxaparin use has increased significantly in ICUs after it has been found useful in reducing hospitalization and mortality in COVID-19 patients. I am positive that it is going to be a high yielding addition to our portfolio, and we intend to add more such innovative products into our product line."



The NovaGuard<sup>®</sup> SA Pro safety system in Cloti-Xa<sup>™</sup>:

- Has been designed to prevent pre-activation during handling;
- Includes tamper-resistant functionality;
- Provides transparency for drug inspection and labeling;
- Is easy to use for healthcare practitioners as it does not require any change in drug administration technique;
- Helps in reducing needlestick injuries and improve OSHA compliance

Speaking on the partnership, Mr. Alagu Subramaniam, Managing Director, West India said, "we are excited to extend our partnership with Venus Remedies on this new product launch. By delivering unique and innovative packaging products and services, we at West are committed to improving patients' health. This partnership helps us bring the benefits of our innovative NovaGuard<sup>®</sup> SA Pro safety system to the India market and we will continue to extend the range of our innovative products to local customers and patients worldwide."

The NovaGuard® SA Pro 1mL safety system has FDA 510k clearance in the U.S. and meets the European 2010/32/EU directive for the prevention of sharps injuries. Designed for both cut and circular syringe flange, the NovaGuard<sup>®</sup> SA Pro safety system has design features that lock when used and has minimal impact upon syringe filling lines.

The NovaGuard<sup>®</sup> SA Pro safety system has also won the India Packaging Awards for Excellence in Enhanced User Experience and Excellence in Packaging Design – Shapes and Structures during the UBM InnoPack Pharma Conference's India Packaging Awards ceremony.

For more information on the NovaGuard<sup>®</sup> SA Pro safety system, visit https://www.westpharma.com/products/prefillable-systems/safety-systems/novaguard-sa-pro

NovaGuard<sup>®</sup> is a registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.

Cloti-Xa is a registered trademark of Venus Remedies in Haryana, India.

###

### About Yenus Remedies:

Venus Remedies, headquartered in Panchkula, Haryana (India), is a research and development driven global pharmaceutical company and among the leading injectable manufacturers in the



world. The company has three manufacturing units, located in Panchkula (India), Baddi (India) and Werne (Germany), and 11 overseas marketing offices.

The manufacturing units are certified with 20+ national and International Accreditations, including EU-GMP, TGA-Australia, among many others. The company has an international presence in 70+ countries, covering over 75 products, with a focus on critical care and oncology. VRL is one of the very few R&D-driven companies in the world working on Antimicrobial Resistance, focusing on novel solutions to tackle the growing threat of superbugs. The Company's R&D centre is approved by the Department of Scientific and Industrial Research, Government of India (DSIR) and is located in Baddi, India.

For more information, visit https://venusremedies.com/

#### About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of lifesaving and life-enhancing medicines for patients. With almost 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 40 billion components and devices each year.

Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2020 generated over \$2.15 billion in sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index.

For more information, visit https://www.westpharma.com/